Want to see ZYBT full AI Analyst Report?
ZYBT Stock Chart & Stats
$1.13
--
Market closed
$1.13
--
Day’s Range― - ―
52-Week Range$0.62 - $13.08
Previous CloseN/A
VolumeN/A
Average Volume (3M)871.70K
Market Cap
$57.96M
Enterprise Value$272.93M
Total Cash (Recent Filing)$51.89M
Total Debt (Recent Filing)$75.08M
Price to Earnings (P/E)―
Beta-0.52
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,965,000
10 Day Avg. Volume198,467
30 Day Avg. Volume871,704
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.52
Price to Sales (P/S)3.27
P/FCF Ratio541.63
Enterprise Value/Market Cap4.71
Enterprise Value/Revenue3.41
Enterprise Value/Gross Profit41.08
Enterprise Value/Ebitda-6.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate LeverageModerate leverage and a sizable equity base provide a financial cushion during the earnings downturn. This supports continued operations and leaves more flexibility than a highly indebted balance sheet if management must fund recovery initiatives.
Positive Operating Cash FlowThe company continued generating positive operating cash flow even during its loss year, indicating that its core operations still produce cash. Although conversion weakened materially, this provides some internal funding capacity and reduces immediate reliance on external capital.
Integrated Animal-Health PlatformA broad veterinary vaccine portfolio, geographic reach and vertically integrated GMP-compliant facilities can support product availability, regulatory consistency and customer coverage. These capabilities create an operating platform for rebuilding demand over the medium term.
Bears Say
Sustained Revenue ContractionThe multi-year revenue decline suggests more than a temporary quarterly disruption and raises concerns about demand, pricing, market position or execution. Without a durable recovery in sales, fixed costs and investment spending may remain difficult to support.
Severe Profitability BreakdownThe shift from positive earnings to a very large net loss materially weakens retained capital and reduces the company’s ability to self-finance growth. Persistently negative operating profitability would also pressure future returns and capital flexibility.
Thin And Volatile Free Cash FlowCash generation has deteriorated sharply and free cash flow is now barely positive after stronger prior periods, including 36.6M in 2023. Thin, volatile cash generation limits funding for product development, capacity and potential recovery efforts.
Zhengye Biotechnology Holding Ltd. News
ZYBT FAQ
What was Zhengye Biotechnology Holding Ltd.’s price range in the past 12 months?
Zhengye Biotechnology Holding Ltd. lowest stock price was $0.61 and its highest was $13.08 in the past 12 months.
What is Zhengye Biotechnology Holding Ltd.’s market cap?
Zhengye Biotechnology Holding Ltd.’s market cap is $57.96M.
When is Zhengye Biotechnology Holding Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zhengye Biotechnology Holding Ltd.’s earnings last quarter?
Currently, no data Available
Is Zhengye Biotechnology Holding Ltd. overvalued?
According to Wall Street analysts Zhengye Biotechnology Holding Ltd.’s price is currently Overvalued.
Does Zhengye Biotechnology Holding Ltd. pay dividends?
Zhengye Biotechnology Holding Ltd. does not currently pay dividends.
What is Zhengye Biotechnology Holding Ltd.’s EPS estimate?
Zhengye Biotechnology Holding Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhengye Biotechnology Holding Ltd. have?
Zhengye Biotechnology Holding Ltd. has 10,965,000 shares outstanding.
What happened to Zhengye Biotechnology Holding Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zhengye Biotechnology Holding Ltd.?
Currently, no hedge funds are holding shares in ZYBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhengye Biotechnology Holding Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.57%
Trailing 12-Months
Company Description
Zhengye Biotechnology Holding Ltd.
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.
Technical Analysis
China Pharma Holdings
―
Aytu BioScience
―
China SXT Pharmaceuticals
―
Qilian International Holding Group Limited
―
Universe Pharmaceuticals
―
Ownership Overview
―
Insiders
0.27% Mutual Funds
0.12% Other Institutional Investors
99.62% Public Companies and
Individual Investors